Analyst Update: Aptevo Therapeutics Inc, PBF Energy Inc, and Cyberark Software Ltd

Analysts are weighing in on biotech Aptevo Therapeutics Inc (NASDAQ:APVO), petroleum refiner PBF Energy Inc (NYSE:PBF), and tech stock Cyberark Software Ltd (NASDAQ:CYBR). Here's a quick roundup of today's brokerage notes on APVO, PBF, and CYBR.

• APVO is up 12.5% at $2.48, after Piper Jaffray initiated coverage with an "overweight" opinion and a $7 price target, calling the biotech stock a "value-play." Aptevo Therapeutics Inc is new to Wall Street, opening for public trade less than two months ago and hitting a record high of $8.29 in late July. Obviously, it's had a rough time on the charts since then -- today notwithstanding -- attracting bearish traders all the while. For instance, over 9% of APVO's float is currently sold short. 
  
  
• PBF has dropped 7% to trade at $21.35, after Goldman Sachs downgraded the stock to "sell" from "neutral," and cut its price target to $10 from $23 -- citing several factors, including a poor outlook for East Coast refining. Most analysts are already bearish on PBF Energy Inc, with 60% giving it a "hold" or a "sell" rating. At the same time, more price-target cuts could come the stock's way if it adds to its 42% year-to-date loss. Specifically, PBF's average 12-month price target stands at $28.83, well above current levels.
  
  
• UBS initiated coverage on CYBR with a "neutral" rating and a $56 price target, yet the stock is 5.3% lower at $51.98 amid broad-market headwinds. Still, the shares appear to be finding support near the $51 level, an area that's contained their pullbacks since early July. Cyberark Software Ltd remains 15.1% higher in 2016, and most analysts seem very optimistic. For instance, 11 of 13 brokerage firms recommend buying the stock, and none consider it a "sell."